Literature DB >> 21606171

Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis.

Ashutosh D Wechalekar, Julian D Gillmore, Nancy Wassef, Helen J Lachmann, Carol Whelan, Philip N Hawkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21606171      PMCID： PMC3128232          DOI： 10.3324/haematol.2011.040493

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

Review 1.  Diagnosis and management of the cardiac amyloidoses.

Authors:  Rodney H Falk
Journal:  Circulation       Date:  2005-09-27       Impact factor: 29.690

2.  Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Authors:  Giovanni Palladini; Francesca Lavatelli; Paola Russo; Stefano Perlini; Vittorio Perfetti; Tiziana Bosoni; Laura Obici; Arthur R Bradwell; GianVico Melzi D'Eril; Roberto Fogari; Remigio Moratti; Giampaolo Merlini
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

Review 3.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Authors:  Morie A Gertz; Ray Comenzo; Rodney H Falk; Jean Paul Fermand; Bouke P Hazenberg; Philip N Hawkins; Giampaolo Merlini; Philippe Moreau; Pierre Ronco; Vaishali Sanchorawala; Orhan Sezer; Alan Solomon; Giles Grateau
Journal:  Am J Hematol       Date:  2005-08       Impact factor: 10.047

4.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

5.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

6.  Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

Authors:  Giovanni Palladini; Vittorio Perfetti; Laura Obici; Riccardo Caccialanza; Alessandra Semino; Fausto Adami; Giobatta Cavallero; Roberto Rustichelli; Giovambattista Virga; Giampaolo Merlini
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113

7.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Philip R Greipp; Thomas E Witzig; John A Lust; S Vincent Rajkumar; Rafael Fonseca; Steven R Zeldenrust; Christopher G A McGregor; Allan S Jaffe
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

Review 8.  Amyloidosis.

Authors:  Mark B Pepys
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

9.  Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Hugh J B Goodman; Helen J Lachmann; Mark Offer; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113
  9 in total
  6 in total

1.  Cardiovascular magnetic resonance myocardial T1 mapping to detect and quantify cardiac involvement in familial amyloid polyneuropathy.

Authors:  Seitaro Oda; Daisuke Utsunomiya; Kosuke Morita; Takeshi Nakaura; Hideaki Yuki; Masafumi Kidoh; Kenichiro Hirata; Narumi Taguchi; Noriko Tsuda; Shinya Shiraishi; Tomohiro Namimoto; Kyoko Hirakawa; Seiji Takashio; Yasuhiro Izumiya; Megumi Yamamuro; Seiji Hokimoto; Kenichi Tsujita; Mitsuharu Ueda; Taro Yamashita; Yukio Ando; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2017-05-05       Impact factor: 5.315

2.  Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.

Authors:  Mohammed A Aljama; M Hasib Sidiqi; Angela Dispenzieri; Morie A Gertz; Martha Q Lacy; Francis K Buadi; David Dingli; Eli Muchtar; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Rahma M Warsame; Taxiarchis Kourelis; Yi Lisa Hwa; Prashant Kapoor; Nelson Leung; Ronald S Go; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Blood Adv       Date:  2019-04-23

3.  Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.

Authors:  Faye A Sharpley; Marianna Fontana; Ana Martinez-Naharro; Richa Manwani; Shameem Mahmood; Sajitha Sachchithanantham; Helen J Lachmann; Julian D Gillmore; Carol J Whelan; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

4.  Updates in cardiac amyloidosis: a review.

Authors:  Sanjay M Banypersad; James C Moon; Carol Whelan; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

5.  N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.

Authors:  Paolo Milani; S Vincent Rajkumar; Giampaolo Merlini; Shaji Kumar; Morie A Gertz; Giovanni Palladini; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Nelson Leung; David Dingli; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Yi L Hwa; Wilson I Gonsalves; Steven R Zeldenrust; Robert A Kyle; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2016-08-29       Impact factor: 10.047

Review 6.  Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist.

Authors:  Federico Perfetto; Mattia Zampieri; Carlo Fumagalli; Marco Allinovi; Francesco Cappelli
Journal:  Intern Emerg Med       Date:  2022-03-24       Impact factor: 5.472
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.